Department of Hepatobiliary Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China.
Sun Yat-Sen University Cancer Center, State Key Laboratory of Southern China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China.
Cancer Biomark. 2018;22(4):611-619. doi: 10.3233/CBM-170091.
Transforming acidic coiled-coil protein 2 (TACC2) is a member of TACC family proteins which is mainly involved in the stabilization of spindles and regulation of microtubule dynamics through interactions with molecules involved in centrosomes/microtubules. TACC2 is involved in tumorigenesis of variety of cancers but the clinical significance of TACC2 protein in hepatocellular carcinoma (HCC) is still unclear.
This study aims to investigate the expression of TACC2 in HCC and determine if clinical significance and prognostic relevance exists.
We performed quantitative PCR (qPCR) and western blot to examine TACC2 mRNA and protein expression in paired HCC tissues and matched adjacent non-cancerous tissues. Immunohistochemistry was performed in 106 postoperative HCC samples.
There was higher expression of TACC2 protein and mRNA in HCC tissue. Immunohistochemistry analysis showed high expression of TACC2 in HCC tissue and was significantly associated with the capsular extension, tumor recurrence and shortened overall and disease free survival. The Cox regression analysis suggested that a high expression of TACC2 was an independent prognostic factor for HCC patients.
This finding suggests that TACC2 may be a useful tool as a candidate biomarker to predict the recurrence and prognosis of HCC.
转化酸性卷曲螺旋蛋白 2(TACC2)是 TACC 家族蛋白的成员,主要通过与中心体/微管相关分子的相互作用参与纺锤体的稳定和微管动力学的调节。TACC2 参与多种癌症的肿瘤发生,但 TACC2 蛋白在肝细胞癌(HCC)中的临床意义尚不清楚。
本研究旨在探讨 TACC2 在 HCC 中的表达情况,并确定其是否具有临床意义和预后相关性。
我们通过定量 PCR(qPCR)和 Western blot 检测了配对的 HCC 组织和匹配的相邻非癌组织中 TACC2 mRNA 和蛋白的表达。对 106 例术后 HCC 样本进行了免疫组织化学分析。
HCC 组织中 TACC2 蛋白和 mRNA 的表达水平较高。免疫组织化学分析显示 HCC 组织中 TACC2 高表达,与包膜延伸、肿瘤复发以及总生存期和无病生存期缩短显著相关。Cox 回归分析提示 TACC2 高表达是 HCC 患者的独立预后因素。
这一发现表明 TACC2 可能是预测 HCC 复发和预后的有用候选生物标志物。